EFFECT OF QRS DURATION ON CARDIAC RESYNCHRONIZATION THERAPY IN PATIENTS WITH HEART FAILURE AND ITS RELATED FACTORS

Main Article Content

Sulaiman Tahir
Nawab Ali
Ashfaq Ahmad Shah Bukhari
Falak Zeb
Maham Khalid
Filza Salim
Abdulaziz Abdullah Raja
Muhammad Haidar Zaman

Keywords

Cardiac resynchronization therapy, LBBB, ECG

Abstract

Background:  Cardiac resynchronization therapy (CRT) is effective in reducing the risk of death and hospitalization and clinical events in systolic heart failure patients with a wide QRS. Previous retrospective studies suggest only patients with QRS prolongation due to a left bundle-branch block (LBBB) benefit from CRT.


Objective: The main purpose of this study was to assess the effect of different durations of QRS on the outcome of CRT / CRTD implantation in patients with heart failure and its subgroups.


Methods: A retrospective cohort study was conducted on 151 heart failure patients receiving CRT / CRTD treatment at Xi'an Jiaotong University's First Affiliated Hospital, from January 2016 to December 2018. The inclusion criteria were QRS duration of approximately 130, left bundle branch block (LBBB) and non-left bundle branch block (NLBBB), LVEF£35%, ischemic and non-ischemic heart disease, N.Y.H.A II-IV. The diagnostic criteria for non-ischemic heart disease include X-ray and echocardiographic tests. The findings of coronary angiography, X-ray, and echocardiography are focused on ischemic heart disease. The observation indexes were ECG's QRS duration before and 12 months after operation. Echocardiography used the Simpson biplane technology to measure the percentage of left ventricular ejection fraction. M-mode was used to measure the changes in left ventricular end-systolic diameter (LVESD), left ventricular end-diastolic diameter (LVEDd), and left atrial size (LA). Comparison has been made of the response of IHD, NIHD, LBBB, and NLBBB groups to CRT.


Results: The QRS morphology was LBBB in 79 cases (52.31%) and NLBBB in 72 cases (47.68%). Cardiac resynchronization therapy appears to be beneficial in patients with QRSd ≥ 150 ms, compared to 130 ms ≤ QRSd ≤ 149 ms patients. The CRT response of NIHD patients was better than that of IHD patients. Both LBBB and NLBBB patients responded in 130 ms ≤ QRSd ≤ 149 ms and QRSd ≥ 150 ms. However, LVEF and LVESV of LBBB patients improved more significantly.


Conclusion: The relative benefit of CRT or CRTD therapy increased with the prolongation of the QRS duration.

Abstract 256 | PDF Downloads 56

References

1. Mann DL, Zipes DP, Libby P, Bonow RO. Braunwald's heart disease e-book: a textbook of cardiovascular medicine. Elsevier Health Sciences; 2014.
2. Halamek J, Leinveber P, Viscor I, et al. The relationship between ECG predictors of cardiac resynchronization therapy benefit. PloS one. 2019;14(5):e0217097.
3. Oka T, Inoue K, Tanaka K, et al. Duration of reverse remodeling response to cardiac
resynchronization therapy: Rates, predictors, and clinical outcomes. International journal of cardiology. 2017;243:340-346.
4. Sassone B, Bertini M, Beltrami M, et al. Relation of QRS duration to response to cardiac
resynchronization therapy in patients with left bundle branch block. The American journal of cardiology. 2017;119(11):1803-1808.
5. Stephansen C, Kronborg MB, Witt CT, et al. Reproducibility of measuring QRS duration and implications for optimization of interventricular pacing delay in cardiac resynchronization therapy. Annals of Noninvasive Electrocardiology. 2019;24(3):e12621.
6. [6] Lei J, Wang YG, Bhatta L, et al. Ventricular geometry–regularized QRSd predicts cardiac resynchronization therapy response: machine learning from crosstalk between electrocardiography and echocardiography. The international journal of cardiovascular imaging. 2019:1-9.
7. Abraham WT, Fisher WG, Smith AL, et al. Cardiac resynchronization in chronic heart failure. New England Journal of Medicine. 2002;346(24):1845-1853.
8. Egoavil CA, Ho RT, Greenspon AJ, Pavri BB. Cardiac resynchronization therapy in patients with right bundle branch block: analysis of pooled data from the MIRACLE and Contak CD trials. Heart Rhythm. 2005;2(6):611-615.
9. Peterson PN, Greiner MA, Qualls LG, et al. QRS duration, bundle-branch block morphology, and outcomes among older patients with heart failure receiving cardiac resynchronization therapy. Jama. 2013;310(6):617-626.
10. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. European journal of heart failure. 2016;18(8):891-975.
11. Stewart S, Horowitz JD. Home-based intervention in congestive heart failure: long-term
implications on readmission and survival. Circulation. 2002;105(24):2861-2866.
12. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Journal of the American College of Cardiology. 2013;62(16):e147-e239.
13. Strauss DG, Loring Z, Selvester RH, et al. Right, but not left, bundle branch block is associated with large anteroseptal scar. Journal of the American College of Cardiology. 2013;62(11):959-967.
14. Members ATF, Brignole M, Auricchio A, et al. 2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: the Task Force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA). European heart journal. 2013;34(29):2281-2329.
15. Prinzen FW, Vernooy K, Auricchio A. Cardiac resynchronization therapy: state-of-the-art of current applications, guidelines, ongoing trials, and areas of controversy. Circulation.
2013;128(22):2407-2418.
16. Kuschyk J, Naegele H, Heinz-Kuck K, et al. Cardiac contractility modulation treatment in patients with symptomatic heart failure despite optimal medical therapy and cardiac resynchronization therapy (CRT). International journal of cardiology. 2019;277:173-177.
17. Byrne MJ, Helm RH, Daya S, et al. Diminished left ventricular dyssynchrony and impact of resynchronization in failing hearts with right versus left bundle branch block. Journal of the American College of Cardiology. 2007;50(15):1484-1490.
18. Rickard J, Bassiouny M, Cronin EM, et al. Predictors of response to cardiac resynchronization therapy in patients with a non-left bundle branch block morphology. The American journal of cardiology. 2011;108(11):1576-1580.
19. Chandra R, Zolty R, Palma E. A left hemiblock improves cardiac resynchronization therapy outcomes in patients with a right bundle branch block. Clinical cardiology. 2010;33(2):89-93.
20. Fantoni C, Kawabata M, Massaro R, et al. Right and left ventricular activation sequence in patients with heart failure and right bundle branch block: a detailed analysis using three‐dimensional non‐fluoroscopic electroanatomic mapping system. Journal of cardiovascular electrophysiology. 2005;16(2):112-119.
21. Garrigue S, Reuter S, Labeque J-N, et al. Usefulness of biventricular pacing in patients with congestive heart failure and right bundle branch block. American Journal of Cardiology. 2001;88(12):1436-1441.
22. Bilchick KC. Does cardiac resynchronization therapy benefit patients with right bundle branch block: left ventricular free wall pacing: seldom right for right bundle branch block. Circulation: Arrhythmia and Electrophysiology. 2014;7(3):543-552.
23. Kutyifa V, Stockburger M, Daubert JP, et al. PR interval identifies clinical response in patients with non–left bundle branch block: a multicenter automatic defibrillator implantation trial–cardiac resynchronization therapy substudy. Circulation: Arrhythmia and Electrophysiology. 2014;7(4):645-651.
24. Pieske B. Reverse remodeling in heart failure–fact or fiction? European Heart Journal Supplements. 2004;6(suppl_D):D66-D78.
25. Braunschweig F, Linde C, Benson L, Ståhlberg M, Dahlström U, Lund LH. New York Heart Association functional class, QRS duration, and survival in heart failure with reduced ejection fraction: implications for cardiac resychronization therapy. European journal of heart failure. 2017;19(3):366-376.
26. Bristow M. Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION): Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med. 2004;350:2140-2150.
27. Chung ES, Leon AR, Tavazzi L, et al. Results of the Predictors of Response to CRT (PROSPECT) trial. echocardiography. 2008;2608:2616.
28. Cleland J, Freemantle N, Ghio S, et al. Predicting the long-term effects of cardiac
resynchronization therapy on mortality from baseline variables and the early response: a report from the CARE-HF (Cardiac Resynchronization in Heart Failure) trial. Journal of the American College of Cardiology. 2008;52(6):438-445.
29. Beshai JF, Grimm RA, Nagueh SF, et al. Cardiac-resynchronization therapy in heart failure with narrow QRS complexes. New England Journal of Medicine. 2007;357(24):2461-2471.
30. Nery PB, Ha AC, Keren A, Birnie DH. Cardiac resynchronization therapy in patients with left ventricular systolic dysfunction and right bundle branch block: a systematic review. Heart Rhythm. 2011;8(7):1083-1087.
31. Iuliano S, Fisher SG, Karasik PE, Fletcher RD, Singh SN, Failure DoVASToATiCH. QRS duration and mortality in patients with congestive heart failure. American heart journal. 2002;143(6):1085-1091.
32. Linde C, Leclercq C, Rex S, et al. Long-term benefits of biventricular pacing in congestive heart failure: results from the MUltisite STimulation in cardiomyopathy (MUSTIC) study. Journal of the American College of Cardiology. 2002;40(1):111-118.
33. Bristow MR, Saxon LA, Boehmer J, et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. New England Journal of Medicine. 2004;350(21):2140-2150.
34. White HD, Norris RM, Brown MA, Brandt PW, Whitlock R, Wild CJ. Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction. Circulation. 1987;76(1):44-51.
35. Bax JJ, Abraham T, Barold SS, et al. Cardiac resynchronization therapy: part 1—issues before device implantation. Journal of the American College of Cardiology. 2005;46(12):2153-2167.
36. Hsing JM, Selzman KA, Leclercq C, et al. Paced left ventricular QRS width and ECG parameters predict outcomes after cardiac resynchronization therapy: PROSPECT-ECG substudy. Circulation: Arrhythmia and Electrophysiology. 2011;4(6):851-857.
37. Iler MA, Hu T, Ayyagari S, et al. Prognostic value of electrocardiographic measurements before and after cardiac resynchronization device implantation in patients with heart failure due to ischemic or nonischemic cardiomyopathy. The American journal of cardiology. 2008;101(3):359-363.
38. Yu C-M, Bleeker GB, Fung JW-H, et al. Left ventricular reverse remodeling but not clinical improvement predicts long-term survival after cardiac resynchronization therapy. Circulation. 2005;112(11):1580-1586.
39. Cleland JG, Daubert J-C, Erdmann E, et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. New England Journal of Medicine. 2005;352(15):1539-1549.
40. Bilchick KC, Kuruvilla S, Hamirani YS, et al. Impact of mechanical activation, scar, and electrical timing on cardiac resynchronization therapy response and clinical outcomes. Journal of the American College of Cardiology. 2014;63(16):1657-1666.
41. Auricchio A, Lumens J, Prinzen FW. Does cardiac resynchronization therapy benefit patients with right bundle branch block: cardiac resynchronization therapy has a role in patients with right bundle branch block. Circulation: Arrhythmia and Electrophysiology. 2014;7(3):532-542.
42. Roman Nevzorov M, Avital Porter M, Shanie Mostov D, et al. Gender-Related Differences in Outcomes of Patients with Cardiac Resynchronization Therapy.
43. Amit G, Suleiman M, Konstantino Y, et al. Sex differences in implantable cardioverterdefibrillator implantation indications and outcomes: lessons from the Nationwide Israeli-ICD Registry. Europace. 2014;16(8):1175-1180.
44. Kelarijani RB, Saleh DK, Chalian M, Kabir A, Asl MA, Dadjoo Y. Gender-and age-related outcomes of cardiac resynchronization therapy: a pilot observational study. Gender medicine. 2008;5(4):415-422.

Most read articles by the same author(s)